Market capitalization | $3.75b |
Enterprise Value | $4.63b |
P/E (TTM) P/E ratio | 32.81 |
EV/FCF (TTM) EV/FCF | 63.42 |
EV/Sales (TTM) EV/Sales | 3.47 |
P/S ratio (TTM) P/S ratio | 2.81 |
P/B ratio (TTM) P/B ratio | 4.14 |
Revenue growth (TTM) Revenue growth | 9.47% |
Revenue (TTM) Revenue | $1.33b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
8 Analysts have issued a Haemonetics Corporation forecast:
8 Analysts have issued a Haemonetics Corporation forecast:
Jun '24 |
+/-
%
|
||
Revenue | 1,334 1,334 |
9%
9%
|
|
Gross Profit | 680 680 |
10%
10%
|
|
EBITDA | 299 299 |
5%
5%
|
EBIT (Operating Income) EBIT | 195 195 |
3%
3%
|
Net Profit | 115 115 |
16%
16%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.
Head office | United States |
CEO | Christopher Simon |
Employees | 3,657 |
Founded | 1971 |
Website | www.haemonetics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.